Eml4-alk fusion gene
AssigneesCureGene K.K., Astellas Pharma Inc.
InventorsHiroyuki Mano, Sadao Kuromitsu, Nobuaki Shindo, Takatoshi Soga, Takashi Furutani
Life of this patent
Estimating the term…
Loading patent…
AssigneesCureGene K.K., Astellas Pharma Inc.
InventorsHiroyuki Mano, Sadao Kuromitsu, Nobuaki Shindo, Takatoshi Soga, Takashi Furutani
Estimating the term…
The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.
An isolated polypeptide comprising the amino acid sequence represented by SEQ ID NO:
(canceled)
(canceled)
A primer set of a sense primer comprising an oligonucleotide with at least any 16 consecutive bases located at base Nos. 1 to 1759 in SEQ ID NO:
A primer set of a sense primer comprising an oligonucleotide with at least any 16 consecutive bases located at base Nos. 1 to 2242 in SEQ ID NO:
A primer set of a sense primer comprising an oligonucleotide with at least any 16 consecutive bases located at base Nos. 1 to 3629 in SEQ ID NO:
A primer set of a sense primer comprising an oligonucleotide with at least any 16 consecutive bases located at base Nos. 1 to 579 in SEQ ID NO:
Dependencies are inferred from the claim text.